Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Despite Eylea's market challenges, Dupixent's strong performance and future ... which translates to an annual yield of ~0.53% - a long way behind the "Big Pharma" average yield of ~3%, but an ...

Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

My name is Tawanda, and I will be your operator ... reflecting the strength and durability of our key franchises, primarily, Dupixent, Libtayo, and EYLEA and EYLEA HD. 2024 was also a year in ...

Secret Lives of Mormon Wives star Mikayla Matthews shared a post on Instagram, in which she gave an update on her journey with chronic illness, sharing that she had her breast implants removed last ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi SNY for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...